May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Neuroprotective Properties of an Anti-VEGF Antibody Delivered by Gene Transfer in the Mouse Retina
Author Affiliations & Notes
  • A. Bemelmans
    Jules-Gonin Eye Hospital, Lausanne, Switzerland
    Unit of Gene Therapy and Stem Cell Biology,
  • C. Kostic
    Jules-Gonin Eye Hospital, Lausanne, Switzerland
    Unit of Gene Therapy and Stem Cell Biology,
  • T. Afanasieva
    Division of Cancer Research,
    University of Zürich, Zürich, Switzerland
  • D. Wanner
    Jules-Gonin Eye Hospital, Lausanne, Switzerland
    Unit of Gene Therapy and Stem Cell Biology,
  • F. L. Munier
    Jules-Gonin Eye Hospital, Lausanne, Switzerland
    Unit of Clinical Oculogenetics,
  • A. Wenzel
    Laboratory of Retinal Cell Biology,
    University of Zürich, Zürich, Switzerland
  • Y. Arsenijevic
    Jules-Gonin Eye Hospital, Lausanne, Switzerland
    Unit of Gene Therapy and Stem Cell Biology,
  • Footnotes
    Commercial Relationships A. Bemelmans, None; C. Kostic, None; T. Afanasieva, None; D. Wanner, None; F.L. Munier, None; A. Wenzel, None; Y. Arsenijevic, None.
  • Footnotes
    Support Supported by Association Française contre les Myopathies
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1692. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Bemelmans, C. Kostic, T. Afanasieva, D. Wanner, F. L. Munier, A. Wenzel, Y. Arsenijevic; Neuroprotective Properties of an Anti-VEGF Antibody Delivered by Gene Transfer in the Mouse Retina. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1692.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: In the retina, the balance between pro- and anti-angiogenic factors is critical for angiogenesis control but is also involved in cell survival and maintenance. Thus, the anti-angiogenic factor PEDF is neuroprotective for photoreceptors in various models of retinal degeneration. We previously reported that, in the light-induced photoreceptor lesion model, retinal expression of VEGF is upregulated, and systemic delivery of PEDF, as well as of an anti-VEGF antibody (scFv-VEGF), rescues photoreceptors from cell death (Wenzel A. et al., ARVO 2004, program #779). We herein describe the effect of scFv-VEGF local delivery by lentiviral gene transfer.

Methods:: We constructed lentiviral vectors coding scFv-VEGF (LV-antiVEGF) or a control scFv (LV-control). Balb/c mice received subretinal injections of the vectors and were subjected to a light-induced lesion (5'000 lux, 1 hr). We next tested the retinal function by electroretinography (ERG), and estimated the photoreceptor survival rate by rhodopsin dosage and transgene expression by quantitative PCR (Q-PCR).

Results:: In vitro data demonstrated that cells transduced by LV-antiVEGF secrete a high amount of scFv-VEGF. In vivo expression after subretinal injection in mice was also assessed by in situ hybridization. We thus treated a group of mice by a subretinal injection of LV-antiVEGF 3 weeks prior to light damage. Control groups received LV-control, vehicle alone, or no pre-treatment. Assessment of the retinal function by ERG 10 days after the lesion showed an average decrease of the a-wave amplitude of 66.6 ±7.3% in control groups compared to naïve animals. After LV-antiVEGF treatment, the average decrease in a-wave amplitude was only of 37.8 ±6.4%, indicating a better survival rate of the photoreceptors (P=0.033). In line with these results, rhodopsin content of the retina was higher in the LV-antiVEGF group than in controls. Moreover, Q-PCR quantification of transgene expression in the RPE layer demonstrated that the extent of photoreceptor protection correlates with the level of anti-VEGF expression (R2=0.781, P=0.0194).

Conclusions:: This study further involves VEGF in light damage and highlights the prime importance of angiogenic factor balance for photoreceptor survival. This suggests that anti-VEGF gene transfer may help to fight retinal diseases by both its neuroprotective and anti-angiogenic actions.

Keywords: gene transfer/gene therapy • photoreceptors • apoptosis/cell death 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×